… of the pharmacokinetic DDI risks of drugs. In this paper, we focus on the methodology of
clinical studies on DDIs involving drug metabolism or transport. We specifically present …

… This chapter explains how drug–drug interactions constitute a significant fraction of avoidable
adverse drug reactions (ADRs). The frequency with which they occur depends, in part, on …

… , quantitatively, potential dietary substance–drug interactions. A key contributing factor to …
drug of interest. The current review provides an update on dietary substance–drug interaction …

… Further work is required regarding a better understanding of the role of the drug
metabolism–drug transport interplay for drug-drug interactions and on the extrapolation of in vitro …

… drugs thereon in clinical drug–drug interaction (DDI) studies. For instance, oral caffeine is
used to quantify hepatic CYP1A2 activity, and oral dagibatran etexilate for intestinal P-…

… the transport−metabolism interplay has also helped in understanding and reinterpreting
absorption and disposition studies of marketed drugs and drug−drug interactions (DDI). In drug …

… Metabolic food-drug interactions occur when the … Just as metabolic drug-drug interactions
can have dramatic clinical … ,[9–11] metabolic food-drug interactions also have the potential for …

… examples of pharmacokinetic drug interaction, which are able to be … drugdrug interaction
can be di‹cult to conˆrm in humans, the identiˆcation of mutations resulting in deˆcient transport …

… The transport and metabolism of drugs in intestine and liver mediates the systemic delivery
of therapeutic compounds, protects the body from drug toxicity, and initiates droves of …

… of drug interactions of new drugs in multicenter trials using the metabolism and transport
drug interaction … Enzyme and Transporter-Based Drug-Drug Interactions Progress and Future …